Global X Genomics & Biotechnology ETF
GNOM
59 hedge funds and large institutions have $31M invested in Global X Genomics & Biotechnology ETF in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 10 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
1.92% less ownership
Funds ownership: 9.26% → 7.35% (-1.9%)
3% less funds holding
Funds holding: 61 → 59 (-2)
15% less capital invested
Capital invested by funds: $36.4M → $31M (-$5.4M)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
33% less call options, than puts
Call options by funds: $2K | Put options by funds: $3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$606K |
| 2 |
OCM
One Capital Management
Westlake Village,
California
|
+$576K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$349K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$323K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$278K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$6.2M |
| 2 |
PWM
Prosperity Wealth Management
San Ramon,
California
|
-$544K |
| 3 |
Lido Advisors
Los Angeles,
California
|
-$219K |
| 4 |
JJBC
James J. Burns & Company
Melville,
New York
|
-$214K |
| 5 |
CF
Centaurus Financial
Anaheim,
California
|
-$147K |
GNOM Hedge Fund Activity: Q1 2024 in Review
59 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q1 2024, worth a combined $31M — down 15% from $36.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GNOM and 8 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 16 added.
The largest buyer was Mirae Asset Global Investments, adding an estimated $606K. The largest seller was Jane Street, cutting an estimated $6.2M.
- 59 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q1 2024, down from 61 in Q4 2023.
- Funds reported $31M of Global X Genomics & Biotechnology ETF stock for Q1 2024, down 15% quarter-over-quarter.
- 8 funds opened new Global X Genomics & Biotechnology ETF positions in Q1 2024 and 10 closed out, a net change of -2 holders.
- The largest Global X Genomics & Biotechnology ETF buyer in Q1 2024 was Mirae Asset Global Investments, an estimated $606K added.
- The largest Global X Genomics & Biotechnology ETF seller in Q1 2024 was Jane Street, an estimated $6.2M sold.
Based on aggregated 13F filings for Q1 2024.